Founded by Yale University scholars and their team returning to China, HebaBiz Biotech is committed to creating personalized, precise and improved solutions for the treatment of cancers and liver diseases, guided by clinical value and patients' needs, and systematically improving the quality of traditional Chinese medicines by the use of cutting-edge biotechnology. Both of our Beijing and Guangxi entities are "National High-tech Enterprises", and our Beijing entity is a "Zhongguancun Hi-Tech Technology Enterprise" and our Guangxi entity is a "Specialized, Excellent, Featured and Innovative Enterprise". HebaBiz Biotech has established a National & Local Joint Engineering Research Center for Anti-tumor Drug Development, systematic technology platforms for small-molecule drugs and innovative traditional Chinese medicines. HebaBiz Biotech has numerous international and domestic patented technologies, and seven new drug candidates in its pipeline under research and development, including China's Category 1.1 Anti-tumor Innovative Drug...
Numerous international and domestic patents
7 pipeline new drugs
And dozens of product approvals
Established a National Anti-tumor Research Center
3 Provincial Research Centers
1 Postdoctoral Research Workstation
68000+ square meters
Quality GMP production workshop
Important Events
-Establishment of the Company
-Dr. James Zhou, Founder of the Company, was awarded "Zhongguancun High-end Leading Talent"
-Dr. James Zhou, Founder of the Company, was awarded "Zhongguancun High-end Leading Talent"
2011
-Establishment of the Company
-Dr. James Zhou, Founder of the Company, was awarded "Zhongguancun High-end Leading Talent"
-Dr. James Zhou, Founder of the Company, was awarded "Zhongguancun High-end Leading Talent"
-The Company was awarded Anti-tumor Drug Development Engineering Research Center of Guangxi Zhuang Autonomous Region
-The Company obtained from Yale University IP rights and global exclusive license for commercial development of Troxacitabine
-The Company obtained from Yale University IP rights and global exclusive license for commercial development of Troxacitabine
2013
-The Company was awarded Anti-tumor Drug Development Engineering Research Center of Guangxi Zhuang Autonomous Region
-The Company obtained from Yale University IP rights and global exclusive license for commercial development of Troxacitabine
-The Company obtained from Yale University IP rights and global exclusive license for commercial development of Troxacitabine
-The Company was awarded the National and Local Joint Engineering Research Center for Anti-tumor Drug Development
-The Company obtained from Yale University IP rights for the structure and the exclusive license for commercial development in China of Clevudine's anti-Hepatitis B virus indications
-Dr. James Zhou, founder of the Company, was awarded the Innovation Talents Promotion Program of the Ministry of Science and Technology
-The Company was awarded "Zhongguancun High-tech Enterprise"
-Investment from Guangxi China-Malaysia Park Industrial Platform Investment Co., Ltd.
-The Company obtained from Yale University IP rights for the structure and the exclusive license for commercial development in China of Clevudine's anti-Hepatitis B virus indications
-Dr. James Zhou, founder of the Company, was awarded the Innovation Talents Promotion Program of the Ministry of Science and Technology
-The Company was awarded "Zhongguancun High-tech Enterprise"
-Investment from Guangxi China-Malaysia Park Industrial Platform Investment Co., Ltd.
2015
-The Company was awarded the National and Local Joint Engineering Research Center for Anti-tumor Drug Development
-The Company obtained from Yale University IP rights for the structure and the exclusive license for commercial development in China of Clevudine's anti-Hepatitis B virus indications
-Dr. James Zhou, founder of the Company, was awarded the Innovation Talents Promotion Program of the Ministry of Science and Technology
-The Company was awarded "Zhongguancun High-tech Enterprise"
-Investment from Guangxi China-Malaysia Park Industrial Platform Investment Co., Ltd.
-The Company obtained from Yale University IP rights for the structure and the exclusive license for commercial development in China of Clevudine's anti-Hepatitis B virus indications
-Dr. James Zhou, founder of the Company, was awarded the Innovation Talents Promotion Program of the Ministry of Science and Technology
-The Company was awarded "Zhongguancun High-tech Enterprise"
-Investment from Guangxi China-Malaysia Park Industrial Platform Investment Co., Ltd.
-Troxacitabine, a category 1.1 anticancer drug, was approved by CFDA for phase I-III clinical trials
-Awarded "The Most Promising Innovative Enterprise" of China Venture Capital Forum
-Awarded "The Most Promising Innovative Enterprise" of China Venture Capital Forum
2016
-Troxacitabine, a category 1.1 anticancer drug, was approved by CFDA for phase I-III clinical trials
-Awarded "The Most Promising Innovative Enterprise" of China Venture Capital Forum
-Awarded "The Most Promising Innovative Enterprise" of China Venture Capital Forum
−The Company was accredited as "National High-tech Enterprise"
−The Company was approved for "Academician Workstation of Guangxi Zhuang Autonomous Region"
−Strategic investment in the Company by Jianfeng Pharmaceutical, a subsidiary of Jianfeng Group (600668.SH)
−The Company was approved for "Academician Workstation of Guangxi Zhuang Autonomous Region"
−Strategic investment in the Company by Jianfeng Pharmaceutical, a subsidiary of Jianfeng Group (600668.SH)
2017
−The Company was accredited as "National High-tech Enterprise"
−The Company was approved for "Academician Workstation of Guangxi Zhuang Autonomous Region"
−Strategic investment in the Company by Jianfeng Pharmaceutical, a subsidiary of Jianfeng Group (600668.SH)
−The Company was approved for "Academician Workstation of Guangxi Zhuang Autonomous Region"
−Strategic investment in the Company by Jianfeng Pharmaceutical, a subsidiary of Jianfeng Group (600668.SH)
-68,000 sqm. production base at China-Malaysia Qinzhou Industrial Park in China (Guangxi) Pilot Free Trade Zone was put into operation
-The Company has obtained global exclusive license, IP rights and proprietary technology for the implementation of Siroquine (JP001)
-The Company has obtained global exclusive license, IP rights and proprietary technology for the implementation of Siroquine (JP001)
2019
-68,000 sqm. production base at China-Malaysia Qinzhou Industrial Park in China (Guangxi) Pilot Free Trade Zone was put into operation
-The Company has obtained global exclusive license, IP rights and proprietary technology for the implementation of Siroquine (JP001)
-The Company has obtained global exclusive license, IP rights and proprietary technology for the implementation of Siroquine (JP001)
-Category 1.1 anti-tumor new drug Troxacitabine commences phase II clinical trial
-Company approved to establish "Workstation of Postdoctoral Scientific Researchers"
-Company approved to establish "Workstation of Postdoctoral Scientific Researchers"
2020
-Category 1.1 anti-tumor new drug Troxacitabine commences phase II clinical trial
-Company approved to establish "Workstation of Postdoctoral Scientific Researchers"
-Company approved to establish "Workstation of Postdoctoral Scientific Researchers"
-Application for clinical trial for anti-tumor new drug Siroquine has been approved by FDA
-Application for phase III clinical trial for potential breakthrough anti-Hepatitis B drug Clevudine has been approved by CDE
-Application for phase III clinical trial for potential breakthrough anti-Hepatitis B drug Clevudine has been approved by CDE
2021
-Application for clinical trial for anti-tumor new drug Siroquine has been approved by FDA
-Application for phase III clinical trial for potential breakthrough anti-Hepatitis B drug Clevudine has been approved by CDE
-Application for phase III clinical trial for potential breakthrough anti-Hepatitis B drug Clevudine has been approved by CDE
Drag the mouse to slide